首页 News 正文

On October 11th local time, the US FDA approved Pfizer's drug Hympavzi (marstalimab) for routine prevention or reduction of bleeding in adult and pediatric patients aged 12 and above with hemophilia A and hemophilia B, who do not contain inhibitors of coagulation factors VIII and IX (neutralizing antibodies).
It is reported that this therapy is the first hemophilia B therapy that only requires subcutaneous injection once a week. It can be used to treat hemophilia A and hemophilia B patients by targeting tissue factor pathway inhibitors (TFPI).
This innovative therapy has been granted fast track status by the US FDA. In phase 2 clinical trials, it was able to reduce the annual bleeding rate of participants by over 75%.
It is worth mentioning that this innovative therapy for hemophilia has also been approved for clinical trials in China.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

芊芊551 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    44